Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Natural Killer(NK) Cell Therapy in r/r AML
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 18
- Registration Number
- NCT05665114
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05658640
- Locations
- 🇦🇹
St. Anna Kinderspital, Vienna, Austria
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇩🇰Rigshospitalet Copenhagen, Copenhagen, Denmark
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 100
- Registration Number
- NCT05660473
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05645718
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 184
- Registration Number
- NCT05628623
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 3
- Registration Number
- NCT05601466
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
- Conditions
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 1
- Registration Number
- NCT05601830
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Vyxeos for Induction of Low- or Intermediate-risk.
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05599360
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: AzacitidineProcedure: Mutation Carrier ScreeningOther: Best PracticeProcedure: Bone Marrow AspirationProcedure: BiopsyDrug: Decitabine and CedazuridineProcedure: Bone Marrow BiopsyDrug: CytarabineDrug: EnasidenibDrug: GilteritinibDrug: Daunorubicin HydrochlorideProcedure: EchocardiographyDrug: Liposome-encapsulated Daunorubicin-CytarabineDrug: VenetoclaxProcedure: Multigated Acquisition Scan
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2000
- Registration Number
- NCT05564390
- Locations
- 🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States
🇺🇸Marshfield Medical Center - Weston, Weston, Wisconsin, United States
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
- Conditions
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 18
- Registration Number
- NCT05558124
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.